should rethink the approach to the science we need to reduce disease burden in this enormous cause of global death and disability.
In this issue of JACC: Basic to Translational Science, products/year to 13 products/year over that time frame. Interestingly, one-half of the drugs entering Phase 3 were targeting a novel biological pathway, which is a trend that increased over time (p ¼ 0.004 for linear trend). This is encouraging because it indicates a priority for truly novel targets in drug development.
This trend towards less relative investment in CV drug development has been previously reported, and a number of issues were addressed in a meeting of experts convened in 2015 (2). As described in the summary paper, the issues are multifactorial including rising drug development costs and perceptions about the concept of "regulatory uncertainty."
The challenge is finding a balance between the imperative to generate evidence to ensure that new drugs entering the market meet a reasonable standard for safety and effectiveness, yet weighing the burden of cost and efficiency that may push investment in innovation into other therapeutic areas. There was a viewpoint that given the large number of beneficial therapies in CV disease, the stringent requirements for demonstration of benefit in clinical outcomes, although justified, may be pushing drug developers to areas in which smaller trials with less stringent clinical outcome measurements are required. 
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Resourcing Drug Development Commensurate With its Public Health Importance A U G U S T 2 0 1 6 : 3 0 9 -1 2 specific subgroups identified which may derive the most benefit from treatment to ensure the highest chance of success in Phase 3-or how often unwarranted optimism drives development following nominally failed Phase 2 studies. One interesting point is that the failure rate in CV disease does not appear to be higher than in other diseases, so perhaps it is not the "uncertainty" that is an issue, but rather the fact that the evidentiary standard requires large, global trials that is holding back investment. Several other recent papers have found that CV drugs are no more likely to fail during or after Phase I than other disease areas (17) . Fiuzat et al.
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